The role of intelligence in phenylketonuria: a review of research and management
- PMID: 20123465
- DOI: 10.1016/j.ymgme.2009.10.015
The role of intelligence in phenylketonuria: a review of research and management
Abstract
Phenylketonuria (PKU) results in profound intellectual disability in untreated individuals and more subtle cognitive deficits in individuals treated early and continuously. The assessment of intellectual functioning has been an important outcome variable and the focus of extensive research. Since the implementation of neonatal PKU screening programs in the 1960s, research on intellectual functioning in individuals with PKU has played a significant and positive role in guiding therapy and improving results. This is a literature review examining the relationship between intellectual outcome and treatment parameters including initiation of treatment, duration of treatment, and blood phenylalanine (Phe) levels from infancy through adulthood. While current PKU treatment practices have eliminated severe neurological and cognitive impairment, evidence suggests that intellectual functioning, although typically within the average range when PKU is treated early and continuously, may not be maximized under the current definition of well-controlled PKU, which is based on blood Phe levels. Future research assessing intellectual and neurocognitive outcome in PKU will enhance the development of new treatment strategies.
Copyright 2009 Elsevier Inc. All rights reserved.
Similar articles
-
Mental health and social functioning in early treated Phenylketonuria: the PKU-COBESO study.Mol Genet Metab. 2013;110 Suppl:S57-61. doi: 10.1016/j.ymgme.2013.10.011. Epub 2013 Oct 22. Mol Genet Metab. 2013. PMID: 24183792
-
Neurocognitive functioning in adults with phenylketonuria: results of a long term study.Mol Genet Metab. 2013;110 Suppl:S44-8. doi: 10.1016/j.ymgme.2013.08.013. Epub 2013 Aug 31. Mol Genet Metab. 2013. PMID: 24071437
-
Stability of blood phenylalanine levels and IQ in children with phenylketonuria.Mol Genet Metab. 2008 Sep-Oct;95(1-2):17-20. doi: 10.1016/j.ymgme.2008.06.014. Epub 2008 Aug 13. Mol Genet Metab. 2008. PMID: 18703366
-
Adult phenylketonuria outcome and management.Mol Genet Metab. 2011;104 Suppl:S26-30. doi: 10.1016/j.ymgme.2011.08.025. Epub 2011 Aug 26. Mol Genet Metab. 2011. PMID: 21944883 Review.
-
Outcomes beyond phenylalanine: an international perspective.Mol Genet Metab. 2010;99 Suppl 1:S79-85. doi: 10.1016/j.ymgme.2009.09.015. Mol Genet Metab. 2010. PMID: 20123476 Review.
Cited by
-
First-year metabolic control guidelines and their impact on future metabolic control and neurocognitive functioning in children with PKU.Mol Genet Metab Rep. 2017 Oct 5;13:90-94. doi: 10.1016/j.ymgmr.2017.09.003. eCollection 2017 Dec. Mol Genet Metab Rep. 2017. PMID: 29021962 Free PMC article.
-
Psychiatric and Cognitive Aspects of Phenylketonuria: The Limitations of Diet and Promise of New Treatments.Front Psychiatry. 2019 Sep 10;10:561. doi: 10.3389/fpsyt.2019.00561. eCollection 2019. Front Psychiatry. 2019. PMID: 31551819 Free PMC article. Review.
-
Classical phenylketonuria presenting as maternal PKU syndrome in the offspring of an intellectually normal woman.JIMD Rep. 2023 Jul 25;64(5):312-316. doi: 10.1002/jmd2.12384. eCollection 2023 Sep. JIMD Rep. 2023. PMID: 37701331 Free PMC article.
-
Caring for children with phenylketonuria.Can Fam Physician. 2013 Aug;59(8):837-40. Can Fam Physician. 2013. PMID: 23946023 Free PMC article. Review.
-
Children and Adolescents with Early Treated Phenylketonuria: Cognitive Development and Fluctuations of Blood Phenylalanine Levels.Int J Environ Res Public Health. 2024 Apr 2;21(4):431. doi: 10.3390/ijerph21040431. Int J Environ Res Public Health. 2024. PMID: 38673342 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical